All In Biotech

Drug Trial Radar · NCT04516278

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders, NORSE THREE

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

197

Actual

Start

Oct 1, 2020

Primary completion

Feb 10, 2021

Study completion Feb 10, 2021

Sponsor

Lead sponsor
Outlook Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the safety of ophthalmic bevacizumab in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion.

Conditions

  • Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Wet Macular Degeneration
  • BRVO - Branch Retinal Vein Occlusion
  • Diabetic Macular Edema

Interventions

  • bevacizumabBiological

    1.25 mg, intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: 3 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Tucson, Arizona

  • Clinical Site

    Beverly Hills, California

  • Clinical Site

    Glendale, California

  • Clinical Site

    Long Beach, California

  • Clinical Site

    Palm Desert, California

  • Clinical Site

    Poway, California

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Winter Haven, Florida

  • Clinical Site

    Oak Forest, Illinois

  • Clinical Site

    Springfield, Illinois

  • Clinical Site

    Hagerstown, Maryland

  • Clinical Site

    Albuquerque, New Mexico

  • Clinical Site

    Chambersburg, Pennsylvania

  • Clinical Site

    Rapid City, South Dakota

  • Clinical Site

    Germantown, Tennessee

  • Clinical Site

    Abilene, Texas

  • Clinical Site

    Arlington, Texas

  • Clinical Site

    McAllen, Texas

  • Clinical Site

    San Antonio, Texas

  • Clinical Site

    Willow Park, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.